(Public, NASDAQ:CPHD)   Watch this stock  
Find more results for CPHD
-0.34 (-1.04%)
Real-time:   2:47PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 32.23 - 32.99
52 week 25.09 - 58.85
Open 32.89
Vol / Avg. 362,962.00/670,211.00
Mkt cap 2.36B
P/E     -
Div/yield     -
EPS -0.78
Shares 72.89M
Beta 0.33
Inst. own 99%
Jul 28, 2016
Q2 2016 Cepheid Earnings Call - 5:00PM EDT - Add to calendar
Jul 28, 2016
Q2 2016 Cepheid Earnings Release - 4:00PM EDT - Add to calendar
Jun 15, 2016
Cepheid at William Blair Growth Stock Conference
Jun 9, 2016
Cepheid at Goldman Sachs Global Healthcare Conference
Jun 8, 2016
Cepheid at Jefferies Healthcare Conference - Webcast
May 11, 2016
Cepheid at Bank of America Merrill Lynch Health Care Conference - Webcast
Apr 28, 2016
Q1 2016 Cepheid Earnings Call
Apr 28, 2016
Q1 2016 Cepheid Earnings Release
Apr 27, 2016
Cepheid Annual Shareholders Meeting (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -4.56% -9.01%
Operating margin -1.55% -5.73%
EBITD margin - 1.59%
Return on average assets -3.24% -6.03%
Return on average equity -7.09% -13.40%
Employees 1,700 -
CDP Score - -


904 E Caribbean Dr
SUNNYVALE, CA 94089-1189
United States - Map
+1-408-5414191 (Phone)
+1-408-5414192 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

Officers and directors

John L. Bishop Chairman of the Board, Chief Executive Officer
Age: 71
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Warren Charles Kocmond Jr. President, Chief Operating Officer
Age: 56
Bio & Compensation  - Reuters
Daniel E. Madden Chief Financial Officer, Executive Vice President
Age: 48
Bio & Compensation  - Reuters
David H. Persing M.D. Ph.D. Executive Vice President, Chief Medical and Technology Officer, Director
Age: 60
Bio & Compensation  - Reuters
Peter Farrell Executive Vice President - International Commercial Operations
Age: 51
Bio & Compensation  - Reuters
Michael Fitzgerald Executive Vice President, Global Human Resources
Age: 56
Bio & Compensation  - Reuters
Marc Haugen Executive Vice President - Engineering and Operations
Bio & Compensation  - Reuters
Scott A. Campbell Ph.D. Corporate Vice President , Chief Regulatory Officer
Age: 46
Bio & Compensation  - Reuters
Cristina H. Kepner Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
Thomas D. Brown Independent Director
Age: 68
Bio & Compensation  - Reuters